FILING ANALYSIS · MONDAY, NOVEMBER 9
Trevi Therapeutics, Inc. TRVI — 8-K: Results of Operations and Financial Condition
neutral
Trevi Therapeutics reported a cash runway into 2030, funding key clinical milestones, and announced positive developments in its chronic cough treatment programs, including a Phase 3 trial initiation and a positive meeting with the FDA, but no quantified surprises were disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →